Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial

No Thumbnail Available
File version
Author(s)
Kirkham, Bruce
Nash, Peter
Navarra, Sandra
Quebe-Fehling, Erhard
Gaillez, Corine
Sastre, Carlos
Mease, Philip
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location

Virtual

License
Abstract

Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed to evaluate the impact of biologics on resolution of dactylitis are limited.3 We report results of a post hoc analysis evaluating the effect of secukinumab (SEC) on PsA patients with dactylitis, from the FUTURE 5 trial (NCT02404350). Methods: FUTURE 5 is a randomized, double-blinded, placebo-controlled, 2-year phase 3 trial in patients with active PsA. Patients (aged ≥18 years) were randomized 2:2:2:3 to s.c. SEC 300 mg or 150 mg with loading dose (LD), 150 mg without loading dose (NL) or placebo. All groups received SEC or placebo at baseline, weeks (wks) 1, 2 and 3 and then every 4 wks from Wk 4. Exploratory efficacy analysis at Wks 16 and 52 included time to resolution of dactylitis by dactylitis severity, proportion of patients with resolution of dactylitis, ACR 20/50 response and Psoriasis Area and Severity Index (PASI) 90. Results: Of the 996 patients in the trial, 389 (39%) had dactylitis (SEC 150 mg NL [N=103], 150 mg LD [N=80], 300 mg LD [N=82], and placebo [N=124]). The mean (SD) tender joint count, swollen joint count and dactylitis count at baseline was: 24.0 (17.0), 14.5 (11.4) and 4.1 (4.16) and 19.1 (14.8), 9.5 (8.5) and 0, respectively, in patients with (N=389) and without (N=607) dactylitis at baseline. Higher presence of enthesitis, hsCRP and skin disease were also observed in the dactylitis subset. Median time to resolution of dactylitis (days) [95% CI] in patients on SEC 150 mg NL, 150 mg LD, and 300 mg LD, was 85 [61.0, 113.0], 85 [57.0, 119.0] and 57 [30.0, 85.0], respectively. A higher proportion of SEC treated patients achieved resolution of dactylitis, ACR 20/50 and PASI90 responses vs. placebo at Wk16 with further improvements through Wk 52 (Table 1). Resolution of dactylitis based on the number of dactylitis count at baseline (≤2 and ≥3) are shown in Table 2. SEC 300 mg LD was associated with a faster time to resolution of dactylitis and higher ACR50 and PASI90 responses compared to SEC 150 mg. Conclusion: A higher level of disease burden was observed in patients with dactylitis compared to patients without dactylitis. SEC 300 mg was associated with a faster time to resolution of dactylitis, higher resolution of dactylitis irrespective of severity and higher responses on skin and joints.

Journal Title
Conference Title

Arthritis & Rheumatology

Book Title
Edition
Volume

72

Issue

S10

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Clinical sciences

Science & Technology

Life Sciences & Biomedicine

Rheumatology

Persistent link to this record
Citation

Kirkham, B; Nash, P; Navarra, S; Quebe-Fehling, E; Gaillez, C; Sastre, C; Mease, P, Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial, ARTHRITIS & RHEUMATOLOGY, 2020, 72 (S10), pp. 2783-2785